

Omar M A El-Agnaf

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5674469/publications.pdf>

Version: 2024-02-01

81
papers

9,955
citations

71097

41
h-index

60616

81
g-index

84
all docs

84
docs citations

84
times ranked

9853
citing authors

#	ARTICLE	IF	CITATIONS
1	Diagnosis and management of dementia with Lewy bodies. <i>Neurology</i> , 2017, 89, 88-100.	1.1	2,805
2	Detection of oligomeric forms of α -synuclein protein in human plasma as a potential biomarker for Parkinson's disease. <i>FASEB Journal</i> , 2006, 20, 419-425.	0.5	646
3	α -Synuclein implicated in Parkinson's disease is present in extracellular biological fluids, including human plasma. <i>FASEB Journal</i> , 2003, 17, 1-16.	0.5	520
4	Detection of elevated levels of α -synuclein oligomers in CSF from patients with Parkinson disease. <i>Neurology</i> , 2010, 75, 1766-1770.	1.1	449
5	Protein Aggregation in the Brain: The Molecular Basis for Alzheimer's and Parkinson's Diseases. <i>Molecular Medicine</i> , 2008, 14, 451-464.	4.4	445
6	CSF and blood biomarkers for Parkinson's disease. <i>Lancet Neurology</i> , The, 2019, 18, 573-586.	10.2	393
7	Decreased α -synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease. <i>Biochemical and Biophysical Research Communications</i> , 2006, 349, 162-166.	2.1	386
8	Direct quantification of CSF α -synuclein by ELISA and first cross-sectional study in patients with neurodegeneration. <i>Experimental Neurology</i> , 2008, 213, 315-325.	4.1	334
9	Cerebrospinal fluid lysosomal enzymes and alpha-synuclein in Parkinson's disease. <i>Movement Disorders</i> , 2014, 29, 1019-1027.	3.9	223
10	Detection of elevated levels of soluble α -synuclein oligomers in post-mortem brain extracts from patients with dementia with Lewy bodies. <i>Brain</i> , 2008, 132, 1093-1101.	7.6	203
11	Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson's disease. <i>Molecular Neurodegeneration</i> , 2016, 11, 7.	10.8	198
12	A strategy for designing inhibitors of α -synuclein aggregation and toxicity as a novel treatment for Parkinson's disease and related disorders. <i>FASEB Journal</i> , 2004, 18, 1315-1317.	0.5	165
13	Cerebrospinal fluid Tau/ α -synuclein ratio in Parkinson's disease and degenerative dementias. <i>Movement Disorders</i> , 2011, 26, 1428-1435.	3.9	161
14	Baicalein Inhibits Formation of α -Synuclein Oligomers within Living Cells and Prevents A β 2 Peptide Fibrillation and Oligomerisation. <i>ChemBioChem</i> , 2011, 12, 615-624.	2.6	140
15	Differential role of CSF alpha-synuclein species, tau, and A β 242 in Parkinson's Disease. <i>Frontiers in Aging Neuroscience</i> , 2014, 6, 53.	3.4	139
16	Bidirectional gut-to-brain and brain-to-gut propagation of synucleinopathy in non-human primates. <i>Brain</i> , 2020, 143, 1462-1475.	7.6	135
17	Lewy body-like alpha-synuclein inclusions trigger reactive microgliosis prior to nigral degeneration. <i>Journal of Neuroinflammation</i> , 2018, 15, 129.	7.2	131
18	Longitudinal changes in CSF alpha-synuclein species reflect Parkinson's disease progression. <i>Movement Disorders</i> , 2016, 31, 1535-1542.	3.9	120

#	ARTICLE	IF	CITATIONS
19	Generation and characterization of novel conformation-specific monoclonal antibodies for α -synuclein pathology. <i>Neurobiology of Disease</i> , 2015, 79, 81-99.	4.4	116
20	Phosphorylated exogenous alpha-synuclein fibrils exacerbate pathology and induce neuronal dysfunction in mice. <i>Scientific Reports</i> , 2017, 7, 16533.	3.3	110
21	Glucosylation in Parkinson's disease and Alzheimer's disease. <i>Movement Disorders</i> , 2016, 31, 782-790.	3.9	104
22	Parkinson's disease biomarkers based on α -synuclein. <i>Journal of Neurochemistry</i> , 2019, 150, 626-636.	3.9	104
23	Structure activity relationship of phenolic acid inhibitors of α -synuclein fibril formation and toxicity. <i>Frontiers in Aging Neuroscience</i> , 2014, 6, 197.	3.4	103
24	The protective role of AMP-activated protein kinase in alpha-synuclein neurotoxicity in vitro. <i>Neurobiology of Disease</i> , 2014, 63, 1-11.	4.4	97
25	Ginsenoside Rb1 inhibits fibrillation and toxicity of alpha-synuclein and disaggregates preformed fibrils. <i>Neurobiology of Disease</i> , 2015, 74, 89-101.	4.4	90
26	α -Synuclein species as potential cerebrospinal fluid biomarkers for dementia with lewy bodies. <i>Movement Disorders</i> , 2018, 33, 1724-1733.	3.9	79
27	Brain propagation of transduced α -synuclein involves non-fibrillar protein species and is enhanced in α -synuclein null mice. <i>Brain</i> , 2016, 139, 856-870.	7.6	78
28	Differential effects of immunotherapy with antibodies targeting α -synuclein oligomers and fibrils in a transgenic model of synucleinopathy. <i>Neurobiology of Disease</i> , 2017, 104, 85-96.	4.4	72
29	CSF or Serum Neurofilament Light Added to α -Synuclein Panel Discriminates Parkinson's From Controls. <i>Movement Disorders</i> , 2020, 35, 288-295.	3.9	69
30	α -Synuclein phosphorylation at serine 129 occurs after initial protein deposition and inhibits seeded fibril formation and toxicity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, e2109617119.	7.1	60
31	Inhibitors of α -synuclein oligomerization and toxicity: a future therapeutic strategy for Parkinson's disease and related disorders. <i>Experimental Brain Research</i> , 2006, 173, 223-233.	1.5	59
32	Elevated levels of cerebrospinal fluid α -synuclein oligomers in healthy asymptomatic LRRK2 mutation carriers. <i>Frontiers in Aging Neuroscience</i> , 2014, 6, 248.	3.4	59
33	Anti-aging treatments slow propagation of synucleinopathy by restoring lysosomal function. <i>Autophagy</i> , 2016, 12, 1849-1863.	9.1	59
34	A user's guide for α -synuclein biomarker studies in biological fluids: Perianalytical considerations. <i>Movement Disorders</i> , 2017, 32, 1117-1130.	3.9	54
35	Decrease in Plasma Levels of α -Synuclein Is Evident in Patients with Parkinson's Disease after Elimination of Heterophilic Antibody Interference. <i>PLoS ONE</i> , 2015, 10, e0123162.	2.5	54
36	Antibodies against alpha-synuclein: tools and therapies. <i>Journal of Neurochemistry</i> , 2019, 150, 612-625.	3.9	53

#	ARTICLE	IF	CITATIONS
37	Increased levels of CSF total but not oligomeric or phosphorylated forms of alpha-synuclein in patients diagnosed with probable Alzheimer's disease. <i>Scientific Reports</i> , 2017, 7, 40263.	3.3	51
38	Dihydromyricetin and Salvianolic acid B inhibit alpha-synuclein aggregation and enhance chaperone-mediated autophagy. <i>Translational Neurodegeneration</i> , 2019, 8, 18.	8.0	48
39	Î±-Synuclein aggregation in neurodegenerative diseases and its inhibition as a potential therapeutic strategy. <i>Biochemical Society Transactions</i> , 2005, 33, 1106.	3.4	47
40	Î±-Synuclein Levels in Blood Plasma from LRRK2 Mutation Carriers. <i>PLoS ONE</i> , 2012, 7, e52312.	2.5	45
41	Soluble oligomers for the diagnosis of neurodegenerative diseases. <i>Lancet Neurology</i> , The, 2003, 2, 461-462.	10.2	44
42	Antibody-based methods for the measurement of Î±-synuclein concentration in human cerebrospinal fluid – method comparison and round robin study. <i>Journal of Neurochemistry</i> , 2019, 149, 126-138.	3.9	44
43	A novel multiplex assay for simultaneous quantification of total and S129 phosphorylated human alpha-synuclein. <i>Molecular Neurodegeneration</i> , 2016, 11, 61.	10.8	39
44	Diagnostic, Prognostic, and Mechanistic Biomarkers of Diabetes Mellitus-Associated Cognitive Decline. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6144.	4.1	35
45	Increased Î±-synuclein levels in the cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. <i>Journal of Neurology</i> , 2014, 261, 1203-1209.	3.6	34
46	Identification of distinct pathological signatures induced by patient-derived Î±-synuclein structures in nonhuman primates. <i>Science Advances</i> , 2020, 6, eaaz9165.	10.3	34
47	CSF total and oligomeric Î±-Synuclein along with TNF-Î± as risk biomarkers for Parkinson's disease: a study in LRRK2 mutation carriers. <i>Translational Neurodegeneration</i> , 2020, 9, 15.	8.0	32
48	Systemic peptide mediated delivery of an siRNA targeting Î±-syn in the CNS ameliorates the neurodegenerative process in a transgenic model of Lewy body disease. <i>Neurobiology of Disease</i> , 2019, 127, 163-177.	4.4	30
49	Early-onset parkinsonism in a pedigree with phosphoglycerate kinase deficiency and a heterozygous carrier: do PGK-1 mutations contribute to vulnerability to parkinsonism?. <i>Npj Parkinson's Disease</i> , 2017, 3, 13.	5.3	28
50	Ultrasonication-based rapid amplification of Î±-synuclein aggregates in cerebrospinal fluid. <i>Scientific Reports</i> , 2019, 9, 6001.	3.3	28
51	Heterogeneity in Î±-synuclein subtypes and their expression in cortical brain tissue lysates from Lewy body diseases and Alzheimer's disease. <i>Neuropathology and Applied Neurobiology</i> , 2019, 45, 597-608.	3.2	27
52	Ser129 phosphorylation of endogenous Î±-synuclein induced by overexpression of polo-like kinases 2 and 3 in nigral dopamine neurons is not detrimental to their survival and function. <i>Neurobiology of Disease</i> , 2015, 78, 100-114.	4.4	24
53	Tissue-Specific Delivery of CRISPR Therapeutics: Strategies and Mechanisms of Non-Viral Vectors. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7353.	4.1	24
54	Paving the Way toward Personalized Medicine: Current Advances and Challenges in Multi-OMICS Approach in Autism Spectrum Disorder for Biomarkers Discovery and Patient Stratification. <i>Journal of Personalized Medicine</i> , 2021, 11, 41.	2.5	23

#	ARTICLE	IF	CITATIONS
55	Inhibition of alpha-synuclein seeded fibril formation and toxicity by herbal medicinal extracts. <i>BMC Complementary Medicine and Therapies</i> , 2020, 20, 73.	2.7	22
56	Cerebrospinal α -Synuclein Oligomers Reflect Disease Motor Severity in <scp>DeNoPa</scp> Longitudinal Cohort. <i>Movement Disorders</i> , 2021, 36, 2048-2056.	3.9	21
57	Age, Disease Severity and Ethnicity Influence Humoral Responses in a Multi-Ethnic COVID-19 Cohort. <i>Viruses</i> , 2021, 13, 786.	3.3	20
58	Targeting α -synuclein as a therapeutic strategy for Parkinson's disease. <i>Expert Opinion on Therapeutic Targets</i> , 2015, 19, 1351-1360.	3.4	19
59	Natural Alkaloid Compounds as Inhibitors for Alpha-Synuclein Seeded Fibril Formation and Toxicity. <i>Molecules</i> , 2021, 26, 3736.	3.8	19
60	Investigating the presence of doubly phosphorylated α -synuclein at tyrosine 125 and serine 129 in idiopathic Lewy body diseases. <i>Brain Pathology</i> , 2020, 30, 831-843.	4.1	15
61	RT-QuIC Using C-Terminally Truncated α -Synuclein Forms Detects Differences in Seeding Propensity of Different Brain Regions from Synucleinopathies. <i>Biomolecules</i> , 2021, 11, 820.	4.0	14
62	Cerebrospinal Fluid α -Synuclein Species in Cognitive and Movements Disorders. <i>Brain Sciences</i> , 2021, 11, 119.	2.3	14
63	An Optical and Temperature Assisted CMOS ISFET Sensor Array for Robust E. Coli Detection. <i>IEEE Transactions on Biomedical Circuits and Systems</i> , 2021, 15, 497-508.	4.0	13
64	Immune-related biomarkers for Parkinson's disease. <i>Neurobiology of Disease</i> , 2022, 170, 105771.	4.4	13
65	Generation of monoclonal antibodies against phosphorylated α -Synuclein at serine 129: Research tools for synucleinopathies. <i>Neuroscience Letters</i> , 2020, 725, 134899.	2.1	12
66	Towards Acoustic Radiation Free Lamb Wave Resonators for High-Resolution Gravimetric Biosensing. <i>IEEE Sensors Journal</i> , 2021, 21, 2725-2733.	4.7	12
67	Correlated levels of cerebrospinal fluid pathogenic proteins in drug-naïve Parkinson's disease. <i>BMC Neurology</i> , 2019, 19, 113.	1.8	11
68	Identification of Novel Circulating miRNAs in Patients with Acute Ischemic Stroke. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3387.	4.1	11
69	Complex I reductions in the nucleus basalis of Meynert in Lewy body dementia: the role of Lewy bodies. <i>Acta Neuropathologica Communications</i> , 2020, 8, 103.	5.2	10
70	Validation of electrochemiluminescence assays for highly sensitive and reproducible quantification of α -synuclein in cerebrospinal fluid. <i>Bioanalysis</i> , 2017, 9, 621-630.	1.5	9
71	Fibrillar form of α -synuclein-specific scFv antibody inhibits α -synuclein seeds induced aggregation and toxicity. <i>Scientific Reports</i> , 2020, 10, 8137.	3.3	9
72	Novel engineered nanobodies specific for N-terminal region of alpha-synuclein recognize Lewy body pathology and inhibit <i>in vitro</i> seeded aggregation and toxicity. <i>FEBS Journal</i> , 2022, 289, 4657-4673.	4.7	9

#	ARTICLE	IF	CITATIONS
73	Prion-like α -synuclein pathology in the brain of infants with Krabbe disease. <i>Brain</i> , 2022, 145, 1257-1263.	7.6	9
74	Cognitive impairment in Parkinson's disease. <i>Lancet Neurology</i> , The, 2017, 16, 23-24.	10.2	7
75	CSF Biomarkers Reflecting Protein Pathology and Axonal Degeneration Are Associated with Memory, Attentional, and Executive Functioning in Early-Stage Parkinson's Disease. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8519.	4.1	7
76	A First Tetraplex Assay for the Simultaneous Quantification of Total α -Synuclein, Tau, β -Amyloid42 and DJ-1 in Human Cerebrospinal Fluid. <i>PLoS ONE</i> , 2016, 11, e0153564.	2.5	6
77	Expression, purification and characterization of α -synuclein fibrillar specific scFv from inclusion bodies. <i>PLoS ONE</i> , 2020, 15, e0241773.	2.5	6
78	Plasma-derived therapy: can the survivors of COVID-19 help the defenseless?. <i>Diagnosis</i> , 2020, 7, 373-376.	1.9	2
79	Rapid Assessment of CRISPR Transfection Efficiency and Enrichment of CRISPR Induced Mutations Using a Dual-Fluorescent Stable Reporter System. <i>Frontiers in Genome Editing</i> , 2022, 4, 854866.	5.2	2
80	P2463: Performance Evaluation of New Absorbance-Based Elisas for Measuring Different Alpha-Synuclein (α -SYN) Species in CSF and Plasma. <i>Alzheimer's and Dementia</i> , 2016, 12, P677.	0.8	1
81	P4316: Standardization of Pre-Analytical Procedures for Collection and Storage of CSF for the Measurement of Neurogranin Trunc P75 and α -Synuclein. <i>Alzheimer's and Dementia</i> , 2016, 12, P1155.	0.8	0